Overall market sentiment has been high on Teva Pharmaceutical Industries Ltd (TEVA) stock lately. TEVA receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With TEVA Stock Today?
Teva Pharmaceutical Industries Ltd (TEVA) stock is trading at $10.81 as of 3:00 PM on Tuesday, Jan 5, a gain of $0.47, or 4.5% from the previous closing price of $10.34. The stock has traded between $10.05 and $11.04 so far today. Volume today is above average. So far 20,172,094 shares have traded compared to average volume of 7,586,625 shares.
To see the top 5 stocks in the Drug Manufacturers - Specialty & Generic industry click here.
More About Teva Pharmaceutical Industries Ltd
Headquartered in Israel, Teva Pharmaceutical is the largest generic drug manufacturer in the world with roughly 60 manufacturing and R&D facilities. The company was formed in 1901 and has a portfolio of more than 3,500 medicines--roughly 1 out of 9 generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva's generic drug sales represent slightly over half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending Food and Drug Administration approval.
Click Here to get the full Stock Score Report on Teva Pharmaceutical Industries Ltd (TEVA) Stock.
